65,437 trials
Diabetic Foot Ulcers
Primary: The Primary Variable for Effectiveness of the dermaPACE Device Will be Assessed by Comparing the Incidence of Complete Wound Closure of the dermaPACE and Control Groups…
Rheumatoid Arthritis
Primary: Change From Baseline in 24-hour Mean Ambulatory SBP — 4.3; 1.3 mmHg — p=0.023
Erectile Dysfunction
Primary: Assess the Ease of Deflation of the Titan® OTR Pump — 70.8 % of participants meeting success criter
Type 1 Diabetes
Primary: Mean Morning Blood Glucose (mg/dL)- Algorithm 1 — 158; 125 mg/dl
Cardiac Arrest · Cardiopulmonary Resuscitation
Primary: Hospital Discharge — 196; 233 participants
Stress Urinary Incontinence
Primary: Patient Satisfaction Using the Patient Global Impression of Improvement (PGI-I) — 41.9 % of subjects successful
Hematologic Malignancies · Graft vs Host Disease
Primary: 100-day Cumulative Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD) — 22 percentage of participants
Glenohumeral Osteoarthritis
Primary: Visual Analog Scale (VAS) Pain Score (Per Protocol) — 30.389; 28.917 mm on a 100 mm VAS scale — p=0.696
Cervical Cancer · Nonneoplastic Condition · Precancerous Condition
Primary: Safety, in Terms of Grade 3 or 4 Adverse Events Attributed to the Vaccine, According to NCI CTCAE v3.0 — 6.0 Grade 3/4 adverse events per 100 patient
Adult Rhabdomyosarcoma · Embryonal Childhood Rhabdomyosarcoma · Embryonal-botryoid Childhood Rhabdomyosarcoma
Primary: Percentage of Patients With Low-risk Rhabdomyosarcoma in Subset 1 Failure Free at 5 Years Following Study Entry — 87; 67 Estimated percentage of participants
HIV Infections
Primary: Maximum Observed Plasma Concentration (Cmax) and Plasma Concentration 24 Hours Post-dose (Cmin) of EFV at Week 2 - Pharmacokinetic Evaluable Population — 3790; 1998…
Smoking Cessation
Primary: Area Under the Curve From Time 0 to Time 't' [AUC(0-t)] of Nicotine 2 mg Test and Reference Product — 11.49; 10.24 hr*ng/mL
Multiple Sclerosis, Relapsing-Remitting
Primary: Percentage of Relapse Free Subjects (no Relapse) — 56.8; 59.5; 68.3; 43.2 percentage of participants — p=0.221
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period — 0.1; 25.1; 74.8; 30.7 Seconds — p=0.456
Diabetes · Hypertension · Dyslipidemia
Primary: Percent of Patients Achieving Hemoglobin A1C Goal, LDL Cholesterol Goal, and Systolic Blood Pressure Goal From the Enrollment Until the End of the Study — 40.8; 20.4…